Durect shares nosedive on Phase III upset

Durect ($DRRX) disappointed investors with data from a Phase III study of anti-pain drug Posidur that were revealed Thursday, and the developer's share price was down more than 30% as of late this morning. The data failed to show that the drug provided a statistically significant improvement in pain in the 305-patient trial, which studied the safety and efficacy of the drug versus placebo in patients undergoing abdominal surgeries. The study also tested the drug against two comparator treatments in patients who underwent two other types of abdominal surgeries, Dow Jones Newswires reported. Durect release | Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.